InspireMD inks distro deal for CGuard in South Africa

InspireMD (NYSE:NSPR) said today that it inked a deal with Torque Medical to distribute its CGuard Embolic Prevention System in South Africa.

The Israel-based company reported that it will begin the commercial launch for CGuard in South Africa immediately.

“We are extremely pleased with the opportunity to offer CGuard EPS in the South African market. We were approached by some of our key customers in the Vascular Surgery, Interventional Neurology and Interventional Cardiology field who had learned about CGuard EPS through conferences and publications and wanted us to make it available in South Africa,” Craig Goodburn, managing member of Torque Medical, said in prepared remarks. “We see CGuard EPS as a key tool for fighting stroke caused by carotid artery disease in our country.”

“As awareness of CGuard among vascular surgeons, interventional neurologists, and cardiologists continues to grow through real-world experience, word-of-mouth, conference presentations, and publications, we are seeing more and more ‘pull-through’ demand in which treating physicians initiate contact with local distributors to make CGuard available in their market, such as what occurred in South Africa,” InspireMD CEO James Barry said.

“In our view, this is a very significant validation of our technology and a clear reflection of CGuard’s clinical advantages relative to both conventional carotid stents and carotid endarterectomy,” Barry added.

Last year, InspireMD won regulatory approval for its CGuard system and MGuard Prime device in Ecuador.

The post InspireMD inks distro deal for CGuard in South Africa appeared first on MassDevice.

Generex Biotech inks $1m deal to acquire distributor Medisource Partners

Generex Biotechnology, MediSource Partners

Generex Biotechnology said yesterday that it inked a deal to acquire medical and surgical product distributor Medisource Partners in a deal worth approximately $1 million.

Miramar, Fla.-based Generex said that the deal includes all assets of Medisource including its business operations, accounts receivable, inventory, contracts and real estate for $1 million worth of Generex stock, as well as additional cash and stock considerations for achieving certain sales and profit milestones.

“The strategic acquisition of Medisource Partners provides Generex with a value-added service model that fits the corporate mission of NuGenerex Distribution Solutions, adding immediate revenues and profits, while providing significant upside as we integrate the medical and surgical supply business into our current and future MSO networks. The extensive lines of surgical and biological products offered in the Medisource catalogue will enable us to expand our offerings to now include hospital systems, as well as our MSO partners. Our management services will not only integrate purchasing and billing, but will provide better pricing and access to new products, especially biologics, including platelet rich plasma, bone marrow aspirate, cord blood, and bone implants. We are excited that the acquisition of Medisource will provide access to a whole new line of products that not only enhances our current MSO network in the five states, but will eventually support the expansion of our MSO network into 27 states. We are in the process of completing the due diligence on this acquisition, with plans to close the transaction in the coming weeks,” Generex CEO Joe Moscato said in a press release.

Medisource Partners is currently contracted with more than 25 vendors to distribute implants and devices for spinal, hip, knee, foot, ankle, hand and wrist surgeries. The company distributes devices including biologics, durable medical equipment and soft goods, Generex said.

“MediSource Partners was founded in 2009 and designed to be unique amongst its competitors by operating as a service-focused, ‘one stop shop’ for the healthcare professionals it serves. With over 25,000 products in its catalogue, including thirteen lines dedicated to spine, Medisource prides itself on its ability to service everything from small private practices across several disciplines, to entire hospital systems. The large and broad-based inventory allows our client physicians to ‘customize’ their operating environment by selecting and implementing the hardware, biologics, soft goods and ancillary tools they feel most confident in and comfortable with. In addition, the ‘one stop shop’ model reduces the burden placed on support staff tasked with managing multiple reps from multiple vendors and shortens the distribution chain to reduce costs and potential redundancies. The success of this model is demonstrated in Medisource’s ability to offer this client-focused, low-impact service at a pricing matrix often below even standard GPO pricing, thus increasing client profitability and productivity,” Medisource CEO Travis Bird said in a prepared statement.

The post Generex Biotech inks $1m deal to acquire distributor Medisource Partners appeared first on MassDevice.

Owens & Minor inks distribution deal with Scripps Health

Owens-MinorOwens & Minor (Mechanicsville, Va.) has signed a five-year medical and surgical supply distribution agreement with Scripps Health. The financial details of the deal were not disclosed.

Scripps Health is a California-based healthcare system that treats more than 750,000 patients annually. Under the agreement, Owens & Minor will serve Scripps Health’s five acute-care hospital campuses and the non-acute care, outpatient centers and clinics in Southern California.

Get the full story on our sister site, Medical Design & Outsourcing.

The post Owens & Minor inks distribution deal with Scripps Health appeared first on MassDevice.

Reva brings bioresorbable scaffolds to new markets

Reva MedicalReva Medical (ASX:RVA) said this week that it inked four new distribution agreements, bringing its commercial operations to seven European countries.

The San Diego, Calif.-based company said the deals serve to expand the reach of its drug-eluting bioresorbable scaffold, Fantom Encore.

Get the full story at our sister site, Drug Delivery Business News.

The post Reva brings bioresorbable scaffolds to new markets appeared first on MassDevice.

Ascensia inks CGM distro, development deal with Poctech

Ascensia DiabetesAscensia Diabetes Care said this week that inked a deal to co-develop and distribute continuous glucose monitoring systems with device developer Poctech.

According to the terms of the deal, Ascensia will become the exclusive distributor for Poctech’s existing CGM product in 13 selected markets. Ascensia said it plans to start distributing the device in the second half of the year.

Get the full story at our sister site, Drug Delivery Business News.

The post Ascensia inks CGM distro, development deal with Poctech appeared first on MassDevice.

DarioHealth inks U.S. distro deal for digital glucose meter

DarioHealth updated logoDarioHealth (NSDQ:DRIO) said today that it inked a deal with healthcare products provider Better Living Now for the distribution of its blood glucose monitoring system and the DarioEngage digital health program.

According to the terms of the deal, BLN plans to buy DarioHealth’s smart glucose meter and test strips to distribute to its customers. The agreement also enables BLN to provide diabetes management coaching to its customers through the DarioEngage platform on a monthly subscription basis.

Get the full story at our sister site, Drug Delivery Business News.

The post DarioHealth inks U.S. distro deal for digital glucose meter appeared first on MassDevice.

LumiThera inks Italian Valeda distro deal

LumiThera

LumiThera said today that it inked a deal with ophthalmology distributor Miloftalmica to be the exclusive distributor of the Valeda light delivery system, intended to treat dry age-related macular degeneration, across Italy.

Therapy using the Valeda light delivery system consists of a series of light-based treatments to the retinal cells, which Seattle-based LumiThera claims improves energy production and can be used to address inflammation, ischemia and metabolic dysfunction that contribute to the disease.

“Our new exciting partnership with LumiThera is fully consistent with the strategy and growth objectives of Miloftalmica, combining innovation and excellence in technology. LumiThera’s breakthrough light delivery system is a value added to Miloftalmica’s product portfolio. LumiThera indeed enables us to offer the first approved treatment for people suffering from dry AMD, the leading cause of adult blindness worldwide,” Miloftalmica CEO Andrea Pagani said in a prepared statement.

“The distribution agreement with Miloftalmica allows LumiThera to expand commercialization in Europe and establishes a collaboration with a partner providing complementary diagnostic and imaging technologies to our treatment for dry AMD. Miloftalmica is a leader in providing innovative technologies to the ophthalmologist and we are excited to be working with them to provide our treatment for dry AMD,” LumiThera prez & CEO Clark Tedford said in a press release.

In October, LumiThera said that it inked a distribution deal with Nikon (TYO:7731) subsidiary Optos to distribute its Valeda light delivery system.

The post LumiThera inks Italian Valeda distro deal appeared first on MassDevice.

Samsung’s NeuroLogica, MaxQ AI ink collab distro deal

Samsung's NeuroLogica, MaxQ AI

Samsung Electronics (LON:BC94) subsidiary NeuroLogica said today that it inked a distribution deal with MaxQ AI to integrate its artificial intelligence software with NeuroLogica’s medical imaging tech in the U.S. and EU’s acute care marketplace.

Through the deal, NeuroLogica said that it will offer MaxQ’s Accipio IX, part of the AI-company’s FDA-cleared and CE Mark approved Accipio Insight intracranial hemorrhage platform intended to support acute care physicians by identifying patients with suspected intracranial hemorrhage using non-contrast head computed tomography imaging.

“We are honored to partner with MaxQ and their flagship product Accipio Ix. AI is an exciting development in healthcare, and through our joint efforts, we are working to improve diagnostic accuracy and reduce time to treatment for stroke. AI has the potential to revolutionize diagnostics, and this collaboration will bring that potential into the patient’s room through our point of care CT systems,” NeuroLogica COO David Webster said in a prepared release.

The Accipio IX solution will be offered as an additional tool for NeuroLogica’s OmniTom mobile 16-slice CT scanner. NeuroLogica said it will make MaxQ’s AI solutions available for integration into into its mobile stroke units as well.

“Following the recent FDA clearance and CE Mark approval of Accipio Ix, our expanded partnership with Samsung NeuroLogica will further accelerate the commercialization of our AI-powered solutions for the acute care market. Designed for seamless integration into CT and PACS systems, our platform coupled with the unique mobile CT offering of Samsung Neurologica, will bring critical life-saving decisions directly to patients in Mobile Stroke Units and to the bed-side of acute care hospital departments. Intelligent imaging, empowering physicians to make more accurate assessments in any location, at any time,” MaxQ AI commercial operations senior VP Chris Schnee said in a press release.

In August, NeuroLogica won a $250 million maximum firm-fixed-price contract to supply the US Dept. of Defense with radiology systems, accessories and training.

The post Samsung’s NeuroLogica, MaxQ AI ink collab distro deal appeared first on MassDevice.

ivWatch inks distro deal for IV monitoring device

ivWatch logo updatedivWatch said this week that it landed an international partner to manage the distribution of its continuous intravenous monitoring device.

The Hampton, Va.-based company inked a deal with supplier New Medical to distribute its ivWatch Model 400 system in Australia and New Zealand.

Get the full story at our sister site, Drug Delivery Business News.

The post ivWatch inks distro deal for IV monitoring device appeared first on MassDevice.

Valeritas inks Middle East distro deal for V-Go insulin delivery device

Valeritas logo - updatedValeritas (NSDQ:VLRX) said today that it signed an exclusive distribution deal with Julphar for the commercialization of its V-Go wearable insulin delivery device in the member states of the Gulf Cooperation Council.

Valeritas has deals in place to bring its V-Go device to 14 countries and territories, including Australia, Slovenia and Puerto Rico. The company is also working to win regulatory approval for the product in China.

Get the full story at our sister site, Drug Delivery Business News.

The post Valeritas inks Middle East distro deal for V-Go insulin delivery device appeared first on MassDevice.